(VIANEWS) – Shares of ERYTECH PHARMA (CAC 40: ERYP.PA) jumped by a staggering 16.66% to €0.90 at 10:55 EST on Monday, after four successive sessions in a row of losses. CAC 40 is jumping 1.1% to €7,266.61, following the last session’s downward trend. This seems, at the moment, an all-around bullish trend trading session today.
ERYTECH PHARMA’s last close was €0.77, 65.86% under its 52-week high of €2.26.
About ERYTECH PHARMA
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, ERYTECH PHARMA has a trailing twelve months EPS of €-3.99.
Volume
Today’s last reported volume for ERYTECH PHARMA is 176344 which is 72.1% below its average volume of 632106.
More news about ERYTECH PHARMA (ERYP.PA).
